Nuclear effects of G-protein receptor kinase 5 on histone deacetylase 5-regulated gene transcription in heart failure

Circulation: Heart Failure

Volumn 4, Issue 5, 2011, Pages 659-668

  Zhang, Yan ^a   Matkovich, Scot J ^a   Duan, Xiujun ^a   Gold, Jessica I ^b   Koch, Walter J ^b   Dorn II, Gerald W ^a  

^a WASHINGTON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Cardiomyopathy; G protein receptor kinase; Gene expression

Indexed keywords

ANGIOTENSIN II; G PROTEIN RECEPTOR KINASE 5; GLUTAMINE; HISTONE DEACETYLASE 5; LEUCINE; PROTEIN KINASE; UNCLASSIFIED DRUG; G PROTEIN COUPLED RECEPTOR KINASE 5; GREEN FLUORESCENT PROTEIN; GRK5 PROTEIN, HUMAN; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; HDAC5 PROTEIN, MOUSE; HISTONE DEACETYLASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL NUCLEUS; CYTOPLASM; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HEART FAILURE; HEART MUSCLE CELL; HISTONE PHOSPHORYLATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA SEQUENCE; SIGNAL TRANSDUCTION; ANIMAL; DISEASE MODEL; GENETICS; HUMAN; METABOLISM; MOUSE MUTANT; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY; SEQUENCE ANALYSIS; TRANSGENIC MOUSE;

ANGIOTENSIN II; ANIMALS; CELL NUCLEUS; CYTOPLASM; DISEASE MODELS, ANIMAL; G-PROTEIN-COUPLED RECEPTOR KINASE 5; GREEN FLUORESCENT PROTEINS; GTP-BINDING PROTEIN ALPHA SUBUNITS, GQ-G11; HEART FAILURE; HISTONE DEACETYLASES; HUMANS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; PHOSPHORYLATION; SEQUENCE ANALYSIS, RNA; TRANSCRIPTION, GENETIC;

EID: 84863012898     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.111.962563     Document Type: Article

References (47)

1. Dorn GW II. Adrenergic signaling polymorphisms and their impact on cardiovascular disease. Physiol Rev. 2010;90:1013-1062.
2. Dorn GW II. GRK mythology: G-protein receptor kinases in cardiovascular disease. J Mol Med. 2009;87:455-463.
3. Liggett SB, Cresci S, Kelly RJ, Syed FM, Matkovich SJ, Hahn HS, Diwan A, Martini JS, Sparks L, Parekh RR, Spertus JA, Koch WJ, Kardia SL, Dorn GW II. A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med. 2008;14:510-517. (Pubitemid 351655214)
4. Cresci S, Kelly RJ, Cappola TP, Diwan A, Dries D, Kardia SL, Dorn GW II. Clinical and genetic modifiers of long-term survival in heart failure. J Am Coll Cardiol. 2009;54:432-444.
5. Lobmeyer MT, Wang L, Zineh I, Turner ST, Gums JG, Chapman AB, Cooper-De Hoff RM, Beitelshees AL, Bailey KR, Boerwinkle E, Pepine CJ, Johnson JA. Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients. Pharmacogenet Genomics. 2011;21:42-49.
6. Spinelli L, Trimarco V, Di MS, Marino M, Iaccarino G, Trimarco B. L41Q polymorphism of the G protein coupled receptor kinase 5 is associated with left ventricular apical ballooning syndrome. Eur J Heart Fail. 2010;12:13-16.
7. Wang WC, Mihlbachler KA, Bleecker ER, Weiss ST, Liggett SB. A polymorphism of G-protein coupled receptor kinase5 alters agonistpromoted desensitization of beta2-adrenergic receptors. Pharmacogenet Genomics. 2008;18:729-732.
8. Dorn GW II, Liggett SB. Pharmacogenomics of beta-adrenergic receptors and their accessory signaling proteins in heart failure. Clin Transl Sci. 2008;1:255-262.
9. Dorn GW II, Liggett SB. Mechanisms of pharmacogenomic effects of genetic variation within the cardiac adrenergic network in heart failure. Mol Pharmacol. 2009;76:466-480.
10. Johnson LR, Scott MG, Pitcher JA. G protein-coupled receptor kinase 5 contains a DNA-binding nuclear localization sequence. Mol Cell Biol. 2004;24:10169-10179. (Pubitemid 39507857)
11. Martini JS, Raake PW, Vinge LE, DeGeorge BB Jr, Chuprun JK, Harris DM, Gao E, Eckhart AD, Pitcher JA, Koch WJ. Uncovering G proteincoupled receptor kinase-5 as a histone deacetylase kinase in the nucleus of cardiomyocytes. Proc Natl Acad Sci U S A. 2008;105:12457-12462.
12. Zhang CL, McKinsey TA, Chang S, Antos CL, Hill JA, Olson EN. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell. 2002;110:479-488. (Pubitemid 35232291)
13. Vega RB, Harrison BC, Meadows E, Roberts CR, Papst PJ, Olson EN, McKinsey TA. Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5. Mol Cell Biol. 2004;24:8374-8385. (Pubitemid 39245060)
14. D'Angelo DD, Sakata Y, Lorenz JN, Boivin GP, Walsh RA, Liggett SB, Dorn GW II. Transgenic G-alphaq overexpression induces cardiac contractile failure in mice. Proc Natl Acad Sci U S A. 1997;94:8121-8126. (Pubitemid 27343787)
15. Gainetdinov RR, Bohn LM, Walker JK, Laporte SA, Macrae AD, Caron MG, Lefkowitz RJ, Premont RT. Muscarinic supersensitivity and impaired receptor desensitization in G protein-coupled receptor kinase 5-deficient mice. Neuron. 1999;24:1029-1036. (Pubitemid 30017680)
16. Matkovich SJ, Zhang Y, Van Booven DJ, Dorn GW II. Deep mRNA sequencing for in vivo functional analysis of cardiac transcriptional regulators: application to Galphaq. Circ Res. 2010;106:1459-1467.
17. Matkovich SJ, Van Booven DJ, Youker KA, Torre-Amione G, Diwan A, Eschenbacher WH, Dorn LE, Watson MA, Margulies KB, Dorn GW II. Reciprocal regulation of myocardial microRNAs and messenger RNA in human cardiomyopathy and reversal of the microRNA signature by biomechanical support. Circulation. 2009;119:1263-1271.
18. Marinescu VD, Kohane IS, Riva A. The MAPPER database: a multigenome catalog of putative transcription factor binding sites. Nucleic Acids Res. 2005;33:D91-D97. (Pubitemid 40207837)
19. Maere S, Heymans K, Kuiper M. BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics. 2005;21:3448-3449. (Pubitemid 41222459)
20. Dorn GW II, Brown JH. Gq signaling in cardiac adaptation and maladaptation. Trends Cardiovasc Med. 1999;9:26-34. (Pubitemid 29147418)
21. Dorn GW II, Tepe NM, Wu G, Yatani A, Liggett SB. Mechanisms of impaired beta-adrenergic receptor signaling in G (alphaq)-mediated cardiac hypertrophy and ventricular dysfunction. Mol Pharmacol. 2000;57:278-287. (Pubitemid 30084504)
22. Dorn GW II, Tepe NM, Lorenz JN, Koch WJ, Liggett SB. Low-and high-level transgenic expression of beta2-adrenergic receptors differentially affect cardiac hypertrophy and function in Galphaq-overexpressing mice. Proc Natl Acad Sci U S A. 1999;96:6400-6405. (Pubitemid 29256677)
23. Sakata Y, Hoit BD, Liggett SB, Walsh RA, Dorn GW II. Decompensation of pressure-overload hypertrophy in G alpha q-overexpressing mice. Circulation. 1998;97:1488-1495. (Pubitemid 28191305)
24. Aronow BJ, Toyokawa T, Canning A, Haghighi K, Delling U, Kranias E, Molkentin JD, Dorn GW II. Divergent transcriptional responses to independent genetic causes of cardiac hypertrophy. Physiol Genomics. 2001;6:19-28. (Pubitemid 33676471)
25. Yussman MG, Toyokawa T, Odley A, Lynch RA, Wu G, Colbert MC, Aronow BJ, Lorenz JN, Dorn GW II. Mitochondrial death protein Nix is induced in cardiac hypertrophy and triggers apoptotic cardiomyopathy. Nat Med. 2002;8:725-730. (Pubitemid 34778726)
26. Akhter SA, Luttrell LM, Rockman HA, Iaccarino G, Lefkowitz RJ, Koch WJ. Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. Science. 1998;280:574-577. (Pubitemid 28227758)
27. Oka S, Ago T, Kitazono T, Zablocki D, Sadoshima J. The role of redox modulation of class II histone deacetylases in mediating pathological cardiac hypertrophy. J Mol Med. 2009;87:785-791.
28. Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet. 2009;10:32-42.
29. Hong CY, Park JH, Seo KH, Kim JM, Im SY, Lee JW, Choi HS, Lee K. Expression of MIS in the testis is downregulated by tumor necrosis factor alpha through the negative regulation of SF-1 transactivation by NF-kappa B. Mol Cell Biol. 2003;23:6000-6012. (Pubitemid 37013081)
30. McKinsey TA, Zhang CL, Lu J, Olson EN. Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. Nature. 2000;408:106-111.
31. Moresi V, Williams AH, Meadows E, Flynn JM, Potthoff MJ, McAnally J, Shelton JM, Backs J, Klein WH, Richardson JA, Bassel-Duby R, Olson EN. Myogenin and class II HDACs control neurogenic muscle atrophy by inducing E3 ubiquitin ligases. Cell. 2010;143:35-45.
32. Yuan X, Ta TC, Lin M, Evans JR, Dong Y, Bolotin E, Sherman MA, Forman BM, Sladek FM. Identification of an endogenous ligand bound to a native orphan nuclear receptor. Plos One. 2009;4:e5609.
33. Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med. 2001;345:971-980.
34. Fraser JD, Martinez V, Straney R, Briggs MR. DNA binding and transcription activation specificity of hepatocyte nuclear factor 4. Nucleic Acids Res. 1998;26:2702-2707. (Pubitemid 28297385)
35. Lee MS, Kliewer SA, Provencal J, Wright PE, Evans RM. Structure of the retinoid X receptor alpha DNA binding domain: a helix required for homodimeric DNA binding. Science. 1993;260:1117-1121. (Pubitemid 23186785)
36. Song Q, Schmidt AG, Hahn HS, Carr AN, Frank B, Pater L, Gerst M, Young K, Hoit BD, McConnell BK, Haghighi K, Seidman CE, Seidman JG, Dorn GW II, Kranias EG. Rescue of cardiomyocyte dysfunction by phospholamban ablation does not prevent ventricular failure in genetic hypertrophy. J Clin Invest. 2003;111:859-867. (Pubitemid 37074961)
37. Timofeyev V, Porter CA, Tuteja D, Qiu H, Li N, Tang T, Singapuri A, Han PL, Lopez JE, Hammond HK, Chiamvimonvat N. Disruption of adenylyl cyclase type V does not rescue the phenotype of cardiac-specific overexpression of Galphaq protein-induced cardiomyopathy. Am J Physiol Heart Circ Physiol. 2010;299:H1459-H1467.
38. Matkovich SJ, Diwan A, Klanke JL, Hammer DJ, Marreez Y, Odley AM, Brunskill EW, Koch WJ, Schwartz RJ, Dorn GW II. Cardiac-specific ablation of G-protein receptor kinase 2 redefines its roles in heart development and beta-adrenergic signaling. Circ Res. 2006;99:996-1003. (Pubitemid 44657803)
39. Dzimiri N, Muiya P, Andres E, Al-Halees Z. Differential functional expression of human myocardial G protein receptor kinases in left ventricular cardiac diseases. Eur J Pharmacol. 2004;489:167-177. (Pubitemid 38496225)
40. Vinge LE, Oie E, Andersson Y, Grogaard HK, Andersen G, Attramadal H. Myocardial distribution and regulation of GRK and beta-arrestin isoforms in congestive heart failure in rats. Am J Physiol Heart Circ Physiol. 2001;281:H2490-H2499.
41. Yi XP, Gerdes AM, Li F. Myocyte redistribution of GRK2 and GRK5 in hypertensive, heart-failure-prone rats. Hypertension. 2002;39:1058-1063. (Pubitemid 34620124)
42. Koch WJ, Rockman HA, Samama P, Hamilton RA, Bond RA, Milano CA, Lefkowitz RJ. Cardiac function in mice overexpressing the ß-adrenergic receptor kinase or a ßARK inhibitor. Science. 1995;268:1350-1353.
43. Rockman HA, Choi DJ, Rahman NU, Akhter SA, Lefkowitz RJ, Koch WJ. Receptor-specific in vivo desensitization by the G protein-coupled receptor kinase-5 in transgenic mice. Proc Natl Acad Sci U S A. 1996;93:9954-9959. (Pubitemid 26296716)
44. Dzimiri N, Basco C, Moorji A, Afrane B, Al Halees Z. Characterization of lymphocyte beta 2-adrenoceptor signalling in patients with left ventricular volume overload disease. Clin Exp Pharmacol Physiol. 2002;29:181-188. (Pubitemid 34233972)
45. Chen EP, Bittner HB, Akhter SA, Koch WJ, Davis RD. Myocardial function in hearts with transgenic overexpression of the G proteincoupled receptor kinase 5. Ann Thorac Surg. 2001;71:1320-1324. (Pubitemid 32328697)
46. Fukuhara S, Marinissen MJ, Chiariello M, Gutkind JS. Signaling from G protein-coupled receptors to ERK5/Big MAPK 1 involves Galpha q and Galpha 12/13 families of heterotrimeric G proteins: evidence for the existence of a novel Ras AND Rho-independent pathway. J Biol Chem. 2000;275:21730-21736. (Pubitemid 30481882)
47. Liu L, Clipstone NA. Prostaglandin F2alpha inhibits adipocyte differentiation via a G alpha q-calcium-calcineurin-dependent signaling pathway. J Cell Biochem. 2007;100:161-173. (Pubitemid 44958187)